GANs in Peptide Drug Discovery: From De Novo Design to Multi-Property Optimization and Clinical Translation.

Authors

Yanyan Chu, Shanshan Zhang, Bin Pan, Qingbao Zhang, Xin Zhou, Ying Liu, Feng Li

Published in

Probiotics and antimicrobial proteins. Aug 31, 2026. Epub Aug 31, 2026.

Abstract

Peptide drugs are vital for treating intractable diseases, yet traditional discovery is limited by huge sequence space and poor pharmacokinetics. Generative Adversarial Networks (GANs) and related variants (CGAN, WGAN-GP, MPOGAN) are increasingly used as auxiliary computational tools for peptide drug discovery, primarily for de novo sequence exploration and multi-property optimization of antimicrobial, antiviral and anticancer peptides. Reported gains in predicted activity or novelty are study-specific and frequently remain limited to in silico evaluation or early in vitro assays. This review summarizes GAN architectures, database foundations, and diverse applications; discusses major limitations, including multi-label data scarcity and property trade-offs; and proposes future directions, including LLM-assisted annotation and closed-loop AI-experimental platforms. It aims to organize current evidence for AI-driven peptide design, emphasize methodological and translational limitations, and outline a realistic pathway toward clinical translation.

PMID:
42671526
Bibliographic data and abstract were imported from PubMed on 30 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.